Founded in 2020, Oxitope Pharma B.V. is a Dutch biopharmaceutical start-up dedicated to the discovery and development of medicines for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. Oxidative stress can induce formation of oxidation specific epitopes (OSEs) that are key drivers of unhealthy ageing and today’s primary source of morbidity and mortality. OSE-related indications include, amongst others, atherosclerosis, fibrotic liver diseases, organ reperfusion injury, age related macular degeneration, respiratory diseases and bone degeneration. By developing a range of advanced therapies against OSEs, we aim to provide first-in-class therapeutics to halt disease progression and improve patient quality of life. Our core business activities are drug discovery and early clinical development. By developing a portfolio of antibody and gene therapy products, we aim to generate revenue through establishing partnership and licensing deals with industry partners for the clinical development and marketing of our pipeline drugs. Our current pre-clinical portfolio is focused on cardiovascular and inflammatory diseases.